General Information of Drug (ID: DMMEAGO)

Drug Name
BMS-955176 Drug Info
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus-1 infection 1C62 Phase 2 [1]
Cross-matching ID
PubChem CID
60152109
TTD Drug ID
DMMEAGO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK2838232 DMCIGRW Human immunodeficiency virus-1 infection 1C62 Phase 2 [3]
GSK3640254 DMMOWT9 Human immunodeficiency virus infection 1C62 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Maturation (HIV Mat) TT5TOX7 NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02415595) Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
4 Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671.